Cannabis Report
Home > Boards > US OTC > Medical - Drugs >

Nano Mobile Healthcare Inc. (VNTH)

Add VNTH Price Alert      Hide Sticky   Hide Intro
Moderator: ThoughtPower, DANNYBOY666
Search This Board: 
Last Post: 6/19/2018 3:09:13 PM - Followers: 189 - Board type: Free - Posts Today: 8


AS: 100.1 BIL
As of 3/7/2018

Nano Mobile Healthcare Inc.

Partnernering with:

We are developing detection devices based on patented technology invented by the National Aeronautics and Space Administration (“NASA”) that was licensed to Nanobeak, and further sublicensed to us.

Our majority shareholder sublicensed to the Company rights acquired under a license agreement with the National Aeronautics and Space Administration (“NASA”) to certain inventions and patent rights owned by NASA relating to chemical sensing nanotechnology, for use within the United States and its territories. As a result of the sublicense, the Company is now a mobile health technology company that is developing personalized and point-of-care screening using applications based upon chemical sensing methods.

Our sublicense for the use of NASA technology has been extended by three years such that the exclusivity of the underlying patents now ends in 2023, providing us with the additional time we need to advance the healthcare applications when the law enforcement breathalyzer enters the marketplace. 

Before the Vantage Sensor, NASA used the sensor technology to protect the astronauts from harmful gases.

The NASA sensor technology offers nine years of results on the Space Shuttle and the International Space Station.

"The sensor was Awarded the NASA Invention of the Year "

Imagine a World

Business Description

Nano Mobile Healthcare - a mobile health technology company - is developing personalized and point-of-care screening using Apps based upon chemical sensing residing within a Bluetooth device that works with any smartphone, tablet or laptop. With its foundations in advanced nanotechnology, the Company's first product, the Nano Mobile Health Sensor, which is in development, is the convergence of nano-electronics, bio-informatics, and wireless technology to create the next generation mobile health application. The Company has offices in New York City and Mountain View, CA. For more information, please visit us at





UPDATE :  Thu 4/20/2017 3:04 PM

"we are working diligently to get our filings current, as well as to move forward with news"  VNTH President J. Peters
(via an investor's email inquiry & quoted response)


UPDATE :  Friday, 05/26/17 09:36 AM

"just as we worked to get the recent 10K filed, we are working diligently to catch-up on all our filings"
- J. Peters (via an investor's email inquiry & quoted response)
NanoBeak Development <>  Team

Presentation :  Thursday, 05/18/17 10:35 AM

3 Columbus Circle, 15th Floor, New York, NY 10019
Phone: (212) 520-4950 |
Category: Chemical Sensor Technology
Innovation: Nanobeak

NANOBEAK Mobile (Stage 1 lung cancer detection) is the first sensor and app planned to be released in 2018.' - John Groman


News History

USA TODAY - The Future Of Health Care Is Social And Techie

ISSUU - Government Health Care United States Buyers Guide: Winter 2014

Meditek - Could A Smartphone Detect Lung Cancer?

Mobile Health News - Scripps To Test NASA-Developed, Smartphone-Enabled Lung Cancer Sensor


Age: 58

Education: West Scranton High School, 1975; bachelor’s degree, criminal justice, King’s College, 1979; juris doctor, Dickinson School of Law, 1983

Experience: Scranton police officer, 1978-1981; assistant, deputy and executive deputy attorney general with focus on organized crime and drugs, including as director of the Bureau of Narcotics Investigation, attorney general’s office, 1982-1998; director, federal high-intensity drug-tracking area, Philadelphia, 1998-1999; director, all federal high-intensity drug-trafficking areas, national drug czar’s office, 1999-2003; counterterrorism consultant, 2004-present; president and chief executive officer, Nano Mobile Healthcare Inc., 2014-present; president, MSGI Technology Solutions, Inc. (formerly, MSGI Security Solutions, Inc., Media Services Group), 2004-present; executive director, Scranton Cultural Center, 2011-2013; state executive deputy attorney general in charge of communications, 2013-2014.


NEW Board Members Included as of May 30th 2017:

Robert Chicoski. Since 2004 Mr. Chicoski has been the acting CFO for two Boston-based businesses providing contract CFO services for all accounting, finance, tax and bank financing matters as well as other strategic business and corporate matters. From June 2012 through April 2017, Mr. Chicoski was the controller, acting Chief Financial Officer and Private Investor Mentor for GVP Global Corp, a Boston private equity investment company.  Mr. Chicoski has been a Certified Public accountant since 1969. He was the founder, Treasurer and Chief Financial Officer of a start- up company, World Energy Solutions, that was previously listed on the Over the Counter Exchange as XWES and subsequently acquired by EnerNOC in 2015. Mr. Chicoski received a BS in Accounting from Bentley College of Accounting and Finance.

James C. Katzaroff was appointed to serve as a member of the Company’s board of directors. James C. Katzaroff. Mr.  Katzaroff is the founder of Advanced Medical Isotope Corp. (Symbol: ADMD) and was the Chief Executive Officer from 2007 through December 2016.  Mr. Katzaroff continues to serve as a director of ADMD.  ADMD is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for the treatment of non-resectable tumors.   Mr. Katzaroff holds a Bachelor’s Degree in Business Economics from the University of California, Santa Barbara and has completed advanced management courses at the University of Washington.



John Groman

CURRENT:   NANOBEAK Mobile (Stage 1 lung cancer detection) is the first sensor and app planned to be released in 2018.

Education: Harvard Business School

My (John Groman) latest venture is a private medical device company that has a non-invasive, sensor and app that will detect stage one lung cancer as well as other detections offered at the price of $1 per test (wholesale). The technology combines our exclusive NASA license of four issued patents and two pending patents with the biomarker research and human trial data from our medical partner Johns Hopkins along with our own proprietary IP. The Sensor and app provide results in real time and will work with all Smartphones, Tablets, Laptops and Desktops. 

Nanobeak, Inc, May 2013 - Present (4 years 1 month)
Bella Sante, Chairman & Founder  - December 1993 – Present (23 years 6 months)
Eames Capital Partners, LLC March 2013 – Present (4 years 3 months)
Epsilon - Co Founder and EVP November 1969 – January 2000 (30 years 3 months) Greater Boston Area Advertising and database marketing agency


NASA Technology Space Certification

Nano Mobile Healthcare is developing a sensor that will screen for the Volatile Organic Compound signatures in a person’s breath. Our device and application (working with any smart phone, laptop or tablet) will be able to identify the presence of lung cancer from a single exhalation. Results will be able to be viewed by patient and doctor in-the-moment and when treatment options are discussed. The Nano Mobile Sensor was developed to address one of the longest standing unmet medical needs today which involves early stage lung cancer detection and to do so in an affordable, non-invasive, safe and convenient way.



Images and some literature is courtesy of


The Nano Mobile Sensor detects chemicals and Volatile Organic Compounds using Carbon Nanotubes.

The sensor was Awarded the NASA Invention of the Year :



Strategic Partnerships

We have entered into a strategic partnership with Theranostics Laboratory, a translational research company, with offices in the USA and New Zealand. Theranostics Laboratory was founded at the Cleveland Clinic in 2010 and works on subcontracted research, in collaboration with the Auckland Bioengineering Institute (ABI), in New Zealand, and with NASA (via NASA Grant NCC 9-58).

The Auckland Bioengineering Institute is recognized as a world-leader in the field of personalized modeling and is part of the international Virtual Physiologic Human (VPH) project. The Institute has successfully commercialized numerous mHealth technologies, including wireless telemetry systems, wearable sensors and a needle-free injectable system into the US market.

The partnership between the Theranostics Laboratory and the Auckland Bioengineering Institute (ABI) is a strategic alliance for us through which the lab will act as principal investigators for us in the areas of mobile strep detection, mobile virus detection and other related areas including breath sample conditioning methodologies. The partnership gives us access to world-class expertise and skill in the field of personalized modeling..

We are working in conjunction with Nanobeak, LLC, a strategic partner, as well as NASA, to develop a mobile app to be used in connection with our sensor that will enable law enforcement to screen for marijuana use and deliver in-the-moment results to the officer’s smartphone, tablet or laptop in the field. Given the increase of marijuana legalization and decriminalization efforts by a growing number of states, we have made the development of a law enforcement sensor the short-term priority. There is a growing need on the part of law enforcement across the country for a portable sensor to detect marijuana abuse and impaired driving. We also plan to incorporate alcohol detection along with the marijuana sensing capability in one device so that law enforcement can have the capability to detect both alcohol (DUI breathalyzer) and marijuana abuse in a single device. The law enforcement device offers a quicker path to market based on reduced testing and regulatory requirements as compared to a medical diagnostic device.

Regulatory Approval

Our products as well as our research and development activities are regulated by numerous governmental authorities, principally the U.S Food and Drug Administration (FDA), as well as state and foreign regulatory agencies. In the US, we believe that the medical diagnostic devices will be classified by the FDA as Class II medical devices and require clearance through a Form 510K. There can be no assurance that the FDA will provide marketing clearance for the device.

Disease Screening

There are a variety of methods to screen for the presence of disease. We are focused on non-invasive, point of care diagnostics. Following years of research, a number of companies are now in prototype phase with devices that can test the chemical compounds in a person’s breath and identify the early stages of disease. Entry to this market is expected to continue and sharply rise as more prototypes emerge and begin to gain market entry with commercialized products. While companies in development tend to be small and privately owned, there has been entry by larger publicly owned companies that have greater financial reserves, distribution channels and more experience in commercialization. Acquisitions and collaborations by and companies seeking a competitive advantage also affect the competitive environment. This is a global market, evidenced by the emergence of companies bringing competitive solutions from different parts of the world.

New competitors may emerge and may develop products and capabilities which compete directly with our products. No assurance can be given that we will be successful in competing in the industries identified or in other industries that would benefit from our technology.

Customers for our medical diagnostic products is expected to include health care providers such as medical doctors, nurse practitioners and physician assistants.

Narcotics Screening

There are currently a variety of breathalyzer smartphone apps which essentially focus on alcohol detection. We are developing devices to distinguish between alcohol and narcotics and screen for a variety of narcotics both legal and illicit.

Making up the narcotic detection space are both domestic and international organizations that range from small, privately held companies to larger companies that include an array of diagnostic narcotics solutions. Although this market is more developed than disease detection, the space is dominated by a few key players making the possibility for new entrants feasible. Because toxicology screens are the most common type of narcotics testing products on the market, we believe that advanced technology that both detects and monitors discrete drug levels in an individual’s system through exhalation will cause this market to expand. The consumer market for mobile applications which provide detection and ongoing monitoring capabilities is anticipated to be significant.

Customers for our product will include the different areas of law enforcement as well as the different areas of professional and amateur sports. Corporations are also a target area for the narcotics screening technology.


We outsource all of our non-executive functions to Nanobeak, LLC. As of the date of this filing Nanobeak has 18 employees and consultants, both full and part time, most of which are shared with NASA and other contractors. The employees are not presently covered by any collective bargaining agreement.


Cannabis Report
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
VNTH News: Proxy Statement - Other Information (preliminary) (pre 14c) 06/15/2018 06:07:36 AM
VNTH News: Current Report Filing (8-k) 06/15/2018 06:06:28 AM
VNTH News: Statement of Beneficial Ownership (sc 13d) 06/14/2018 09:38:43 AM
VNTH News: Statement of Beneficial Ownership (sc 13d) 06/14/2018 09:38:43 AM
VNTH News: Statement of Beneficial Ownership (sc 13d) 06/14/2018 09:37:25 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#16015  Sticky Note The share structure was altered to comply with DANNYBOY666 03/21/18 03:43:19 PM
#15954  Sticky Note Per the filing only 803,659,018 OS OnceBrokeMama 03/16/18 12:32:57 PM
#16194   Unless he is taking control of Nanobeak as DANNYBOY666 06/19/18 03:09:13 PM
#16193   If that were the case then he would ptcgolf 06/19/18 01:06:20 PM
#16192   If that were so, do you not think DANNYBOY666 06/19/18 01:02:11 PM
#16191   a reverse split will increase the price of Jawbone 06/19/18 11:13:43 AM
#16190   Just an address needed to sell shares. ptcgolf 06/19/18 10:16:13 AM
#16189   It is nothing more than a virtual office gater 06/19/18 09:37:40 AM
#16188   Nothing good ever comes from a RS. Ever. ThoughtPower 06/19/18 08:14:54 AM
#16187   Anybody else notice the companies address has been DANNYBOY666 06/19/18 06:18:14 AM
#16186   Talk about a real screw to all of gater 06/18/18 10:27:54 AM
#16185   That was prety much a direct quote from DANNYBOY666 06/15/18 02:02:15 PM
#16184   In this case to appeal to institutional investors. DANNYBOY666 06/15/18 01:38:46 PM
#16183   well then i hope you exited on the ptcgolf 06/15/18 01:31:03 PM
#16182   So, you knew about the RS... or no? In ThoughtPower 06/15/18 01:30:32 PM
#16181   i only care about capital value not voting DANNYBOY666 06/15/18 01:27:01 PM
#16180   Groman, Finnegan, and Swan voted with 57% of ptcgolf 06/15/18 01:20:42 PM
#16179   remember the c's and d's are worthless until DANNYBOY666 06/15/18 01:04:44 PM
#16178   It’s got me perplexed that is for sure. wedman 06/15/18 12:51:17 PM
#16177   to get cheeps before the split and while DANNYBOY666 06/15/18 12:48:21 PM
#16176   Why is anyone buying this ? wedman 06/15/18 12:18:23 PM
#16175   Last R/S was 3/23/2016 1 for 10 rklbw 06/15/18 11:56:37 AM
#16174   the final ratio has yet to be approved ptcgolf 06/15/18 11:41:29 AM
#16173   I'm trying to understand what was approved. gater 06/15/18 10:40:53 AM
#16172   So predictable with this group. ptcgolf 06/15/18 10:31:36 AM
#16171   My R/S prediction had been in Jan/Feb, ShizlDizl 06/15/18 10:16:01 AM
#16170   as you were saying? 1 for 100,000 enjoy ptcgolf 06/15/18 09:45:12 AM
#16169   bingo ptcgolf 06/15/18 09:17:45 AM
#16168   looks like you're wrong in terms of the Investophile 06/15/18 08:56:08 AM
#16167   PRE 14C shanak10 06/15/18 07:02:08 AM
#16166   Actually there are anti-dilution clauses in their holdings. ptcgolf 06/14/18 04:22:14 PM
#16165   selling 100 shares at close to lower the DANNYBOY666 06/14/18 04:16:31 PM
#16164   preferred cant convert until debt is wiped clean, DANNYBOY666 06/14/18 04:10:41 PM
#16163   I say exactly what i have been...the common ptcgolf 06/14/18 04:03:58 PM
#16162   50 % sustained daily gain is still good DANNYBOY666 06/14/18 04:02:52 PM
#16161   What happened to the 3 bears? gater, ptcgolf, DANNYBOY666 06/14/18 03:53:51 PM
#16160   looks like this might go from open to Investophile 06/14/18 03:29:31 PM
#16159   How about now? Can it come now? This Lo$eitall80 06/14/18 02:47:29 PM
#16158   Yep that is true ! wedman 06/14/18 02:27:21 PM
#16157   but this stock doesn't look to be finishing Investophile 06/14/18 02:06:42 PM
#16156   I think with any kind of decent news, cparma 06/14/18 01:53:42 PM
#16155   I get what you are saying, but dilution DANNYBOY666 06/14/18 01:38:27 PM
#16154   could be. have to wait to see Investophile 06/14/18 01:26:48 PM
#16153   It does look like that to me as well. wedman 06/14/18 01:08:39 PM
#16152   What’s up with the volume today? OnceBrokeMama 06/14/18 01:02:56 PM
#16151   well let me know when that's happening :) Investophile 06/14/18 12:42:36 PM
#16150   RE: Insider selling. DANNYBOY666 06/14/18 12:41:11 PM
#16149   going current in filings, positive clinical trials and DANNYBOY666 06/14/18 12:39:09 PM
#16148   and if the insiders are the ones who Investophile 06/14/18 12:37:30 PM
#16147   interesting. what will take it to .005 Investophile 06/14/18 12:35:43 PM
#16146   Thats why you need to sell before those DANNYBOY666 06/14/18 12:31:29 PM
#16145   100 billion shares is a big "to do" Investophile 06/14/18 12:25:08 PM